Endurant Capital Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-148,400
| Closed | -$156K | – | 2 |
|
|
2023
Q4 | $156K | Buy |
+148,400
| New | +$156K | 0.89% | 25 |
|
|
2023
Q2 | – | Sell |
-83,891
| Closed | -$679K | – | 31 |
|
|
2023
Q1 | $679K | Buy |
+83,891
| New | +$679K | 0.35% | 40 |
|
|
2021
Q4 | – | Sell |
-67,300
| Closed | -$1.21M | – | 66 |
|
|
2021
Q3 | $1.21M | Sell |
67,300
-52,078
| -44% | -$937K | 0.28% | 44 |
|
|
2021
Q2 | $2.1M | Sell |
119,378
-336,007
| -74% | -$5.9M | 0.58% | 47 |
|
|
2021
Q1 | $11.5M | Sell |
455,385
-671,290
| -60% | -$16.9M | 2.99% | 10 |
|
|
2020
Q4 | $7.29M | Sell |
1,126,675
-306,142
| -21% | -$1.98M | 2.63% | 11 |
|
|
2020
Q3 | $3.68M | Sell |
1,432,817
-295,970
| -17% | -$761K | 1.09% | 28 |
|
|
2020
Q2 | $2.8M | Sell |
1,728,787
-890,400
| -34% | -$1.44M | 0.15% | 31 |
|
|
2020
Q1 | $2.72M | Buy |
2,619,187
+564,118
| +27% | +$587K | 1.23% | 22 |
|
|
2019
Q4 | $3.88M | Buy |
2,055,069
+285,284
| +16% | +$539K | 1.22% | 23 |
|
|
2019
Q3 | $1.91M | Buy |
1,769,785
+140,458
| +9% | +$152K | 0.69% | 26 |
|
|
2019
Q2 | $3.57M | Buy |
1,629,327
+1,083,598
| +199% | +$2.37M | 1.41% | 30 |
|
|
2019
Q1 | $3.27M | Buy |
+545,729
| New | +$3.27M | 1.29% | 21 |
|